ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

  • Interventional
  • Not Recruiting
  • NCT02565758
Eligibility Details Visit

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

This is an open-label dose escalation study designed to evaluate the safety and pharmacokinetics of ABBV-085 and determine the recommended Phase 2 dose (as monotherapy or in combination with standard therapies) in subjects with advanced solid tumors.


Age Group
18 Years and up

Accepting Healthy Volunteers?

Inclusion Criteria:

         1. Participants with advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options.

         2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.

         3. Participants must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens:

             - Participants with non-evaluable or non-measurable cancer are eligible if they have a confirmed increase in tumor antigens >=2 x upper limit of normal (ULN).

         4. All participants must consent to provide archived diagnostic formalin-fixed paraffin embedded (FFPE) tumor tissue and on study biopsies.

         5. Participant has adequate bone marrow, renal, hepatic and cardiac function.

         6. Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment.

        Exclusion Criteria:

         1. Participant has received anticancer therapy or any investigational therapy within a period of 21 days prior to the first dose of ABBV-085.

         2. Uncontrolled metastases to the central nervous system (CNS). Participants with brain metastases are eligible provided they have shown clinical and radiographic stable disease for at least 4 weeks after definitive therapy and have not used steroids for at least 4 weeks prior to first dose of ABBV-085.

         3. Unresolved adverse events >= Grade 2 from prior anticancer therapy, except for alopecia.

         4. Participant has ongoing hemolysis.

         5. Major surgery within <=28 days prior to the first dose of ABBV-085.

         6. Clinically significant uncontrolled condition(s).

         7. Participant has history of major immunologic reaction to any auristatin-based and /or Immunoglobulin G (IgG) containing agent.

At a Glance

National Government IDNCT02565758


Lead SponsorAbbVie

Lead PhysicianMark J. Ratain


18 Years and up
Not Recruiting